Zacks Research Brokers Reduce Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE) – Analysts at Zacks Research decreased their Q4 2027 earnings per share (EPS) estimates for Pfizer in a report issued on Tuesday, December 30th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings of $0.70 per share for the quarter, down from their previous estimate of $0.71. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS.

Several other research analysts also recently issued reports on PFE. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Bank of America decreased their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. HSBC restated a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.06.

Pfizer Price Performance

Shares of PFE stock opened at $24.90 on Friday. Pfizer has a 52 week low of $20.92 and a 52 week high of $27.69. The stock has a market capitalization of $141.57 billion, a PE ratio of 14.48 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The stock’s fifty day moving average is $25.17 and its 200-day moving average is $24.90.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s payout ratio is currently 100.00%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Fiduciary Alliance LLC increased its position in Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after buying an additional 46,043 shares during the last quarter. Vista Investment Partners LLC raised its stake in Pfizer by 236.1% in the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after purchasing an additional 48,900 shares in the last quarter. Westbourne Investments Inc. acquired a new stake in Pfizer during the first quarter worth about $2,411,000. Generali Investments CEE investicni spolecnost a.s. raised its position in Pfizer by 76.4% during the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after purchasing an additional 47,319 shares in the last quarter. Finally, Bourne Lent Asset Management Inc. boosted its holdings in shares of Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks raised near-term quarterly EPS outlooks for Q2 2026 and Q2 2027 (small bumps to $0.66 and $0.62 respectively), suggesting some stabilization in earnings momentum. (MarketBeat summary)
• Positive Sentiment: Analysts/industry reports show Pfizer leading drugmakers planning price increases on many branded medications — this could support revenue and margins if implemented. Read More.
• Positive Sentiment: Several value-oriented pieces argue Wall Street has “given up” on Pfizer and that the company looks attractively valued given stabilized revenue and a rebuilding pipeline — these narratives can attract long-term/income investors. Read More.
• Neutral Sentiment: Multiple retail-investor columns (The Motley Fool, NAI500, Kalkine) debate whether Pfizer under $25–$30 is a buy — useful context for retail flows but not an immediate catalyst. Read More. · Read More. · Read More.
• Negative Sentiment: Zacks trimmed its Q4 2027 EPS estimate slightly (to $0.70 from $0.71) and previously cut Q4 2025 estimates; those downward revisions are direct near-term negatives for earnings expectations. (MarketBeat summary)
• Negative Sentiment: TD Cowen maintained a Hold rating for PFE — a lack of upward revisions from a respected shop can cap upside and reinforce cautious positioning. Read More.
• Negative Sentiment: Coverage pieces noting Pfizer’s multi-year pullback from pandemic highs and underperformance vs. the market underscore investor wariness and explain continued selling pressure. Read More.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.